Open access peer-reviewed chapter

Polylipid Nanoparticle, a Novel Lipid-Based Vector for Liver Gene Transfer

By Yahan Fan and Jian Wu

Submitted: April 24th 2012Reviewed: October 11th 2012Published: February 27th 2013

DOI: 10.5772/54270

Downloaded: 1739

1. Introduction

Lipid nanoparticles (LNP) are invaluable carriers for drug and gene delivery, and they are classified as cationic, neutral and anionic depending on the electronic charges existing on the surface of the vesicles [1]. These charges are originated from the charged lipids from which lipid nanoparticles are formulated. Cationic LNP are commonly used for DNA or RNA carriers due to their interaction with negatively-charged nucleotide. Both neutral and negatively-charged LNPs are used for drug delivery [2] and may be formulated as sterically stable LNPs (SSLNPs), which are amendable for cell type-specific or tissue-specific targeting delivery [3]. For liver drug delivery, tremendous efforts have been made to develop cell type-selective lipid-based drug carriers. Effective approaches in targeting hepatocytes, Kupffer cells and hepatic stellate cells have been evaluated in small animals [3, 4], and some of them may be translational to clinical application [5]. These approaches are referable when cationic LNPs are considered for cell type-selective gene delivery. A prerequisite for the success of gene therapy for liver disorders is the development of powerful gene carriers. Non-viral vectors have been very successful for gene transfer in an in vitro setting, in terms of efficiency of lipofection, applicability in variety of cell types, and amending ability of cell type-specific delivery (Fig. 1). The clinical application of LNP-mediated gene transfer has been hampered by low efficiency, instability in the bloodstream, short-term transgene expression and toxicity. These shortcomings are the bottle neck hindering the gene transfer employing LNPs as carriers for delivery of function gene(s) to solid organs, and are the challenges in moving from small to large animals of potential gene carriers and approaches, and in the translation to clinical application. However, the polylipid nanoparticles (PLNP) we have developed over the past decade represent one of the few formulations that are applicable for in vivo gene transfer [6], due to a high DNA-packaging capacity, an extremely low binding rate to serum proteins, low toxicity, and amendable synthetic approaches [7, 8]. This chapter intends to introduce the characteristics of this formulation, and to discuss our efforts in moving the non-viral gene transfer platform from small to large animals towards clinical applications.

Figure 1.

In vivo gene transfer mediated by viral or non-viral vectors. Viral vectors, such as lentiviral or retroviral vectors, which lead to integration of transgene in the host genome, give rise to long-term transgene expression. However, they may cause insertion-induced mutation that is oncogenic. Adenoviral or adeno-associated viral (AAV) vectors often yield a high level of transgene expression in host organs. However, generation of antibodies against viral components is still a concern. Non-viral gene transfer may be achieved by direct plasmid administration with local electroporation or a hydrodynamic approach. The latter is only applicable in mice. Lipid nanoparticle (LNP)-mediated gene transfer becomes a useful approach which is often very successful for in vitro gene transfer. Few formulations of cationic LNPs are valuable for in vivo gene transfer. There has been a still demand in improving their in vivo stability and gene transfer efficacy.

There are a number of critical components for a potential gene therapy product to move from one step to the next in this pipeline. Promisingly, LNP-mediated gene transfection for the treatment of genetic and metabolic disorders or tumors has been moved to clinical trial phases (http://clinicaltrials.gov). A phase I pilot study of gene therapy for cystic fibrosis using cationic liposome-mediated gene transfer (NCT00004471) has been completed. A phase I trial of intratumoral epidermal growth factor receptor (EGFR) antisense DNA delivered by DC-Chol liposomes in advanced head and neck cancer, including oral squamous cell carcinoma (NCT00009841) and DOTAP-Chol-Fus1 liposome-mediated gene therapy for non-small cell lung cancer (NCT00059605] [9] were conducted respectively by University of Pittsburg and MD Anderson Cancer Center in collaboration with the National Cancer Institute (NCI). Fus1 is a tumor suppressive gene that has been shown to be effective in suppressing the growth of original or metastatic lesions of non-small lung cancer when it is delivered locally or systemically [10]. Thus, it appears that genetic therapy using LNPs as gene carriers has the potential to be specially tailored for genetic disorders or cancers.

2. Nanoparticle carriers for drug or gene delivery

Lipid-based gene carriers include liposomes (cationic or anionic), polymer and dendrimer nanoparticles. Cationic liposomes are capable of delivering genes to cells or tissues, and achieving maximal therapeutic efficiency with minimal adverse effects [1]. However, the use of cationic LNPs for in vivo DNA transfection is hindered by substantial problems; i.e. after intravenous administration, cationic LNPs bind to plasma protein and blood cells due to charge reaction. The resulting aggregates of carriers with proteins or cells block microcirculation or may be cleared rapidly [11, 12]. The common formulations for in vivo gene delivery are DOTMA or DOTAP-DOPE or DOTAP-cholesterol (Chol). These formulations are highly serum-reactive [6, 13]. Lungs are the major organ shown to be highly transfected probably due to the accumulation of aggregates of lipoplexes with serum proteins or blood cells when the lipoplexes are administrated intravenously [14]. For this reason, cationic LNPs were once used widely for gene delivery to the lungs; and later for treating lung cancers and metastasis with further optimization [10, 15, 16]. LNP-mediated gene delivery to the liver is more difficult than to lungs. For the development of the gene carriers, cationic LNP formulations, such as DC-Chol, DOTAP-Chol, are available for delivering genes to various tissues [17]. A few LNP formulations targeting hepatocellular carcinoma (HCC) have been developed for improving efficacies of drug therapy [18, 19]. In order to avoid the rapid clearance by the reticuloendothelial system (RES) and to increase the drug delivery through the enhanced permeability and retention (EPR) effect to a tumor site by passive targeting, novel strategies, such as reducing particle size, minimizing rigidity of lipids, generating amphiphilic vesicles and shielding from the recognition by RES system, have been attempted in formulating lipid-based drug/gene carriers [1, 2]. To reduce lysosomal degradation, pH-sensitive LNPs are prepared for drug or gene delivery [20]. These approaches may be instructive in the development of LNPs for gene transfer at different stages of preclinical translation.

Polymeric non-viral vectors have exhibited additional advantages of lower toxicity and immunogenicity [21, 22]. These vectors may offer the possibility of industrial production following good manufacturing practice (GMP). Amphiphilic polyethylene glycol (PEG) has been engineered as a linker, most for coupling peptides to cationic lipids. Other polymers, such as dendritic poly(L-lysine)-b-poly(L-lactide)-b-dendritic vector [23], poly (ethyleneimine) (PEI) [24], poly (methacrylate) [25] and polyamidoamine dendrimers [26], have been demonstrated to be effective for in vitro gene delivery. However, striking issues still exist for cationic polymers regarding whether they are applicable for in vivo gene transfer to solid organs such as the liver, without significant adverse effects.

3. Liver-specific gene delivery

Because of our interest in gene therapy of liver disorders, we have focused our efforts on improving liver-based gene delivery. The pathogenesis of liver injury and fibrosis involves complicated interactions among different cell populations in the liver, soluble factors, such as cytokines and reactive oxygen species (ROS), and the extracellular matrix components. In order to improve the efficacy in preventing hepatocellular injury, the use of LNPs that are capable of delivering hepatoprotective agents to the liver, selectively to hepatocytes, will increase local concentration of therapeutic agents, reduce adverse effects, and achieve maximal therapeutic efficiency. The parenchymal cell type in the liver is hepatocytes, which are responsible for an array of metabolic function in the body and are often damaged in a variety of pathological processes. The asialoglycoprotein receptor (ASGP-R) on mammalian hepatocytes provides a unique means for the development of liver-specific drug or gene carriers. The abundant receptors on hepatocytes specifically recognize the natural ligands, lectin and asialofetuin (AF), as well as those with terminal galactose or N-acetylgalactosamine residues, and hepatocytes endocytose these ligands for an intracellular degradation process [27, 28]. The use of its natural or synthetic ligands, such as galactosylated cholesterol, glycolipids or galactosylated polymers to label LNPs has achieved significant targeting efficacy to the liver [4, 28]. AF-labeled LNPs have been used for improving liver-targeting gene transfer in small animals [29], yet there have not been successful reports available in the translation to large animals, such as pigs [30]. Instead, plasmid DNA was directly administrated into the hepatic vein through a catheter with a balloon closure of hepatic vein blood flow [30]. One particular attention has been drawn in terms of the use of AF-labeled drug carriers for HCC targeting. The expression of ASGP-R in HCC cells varies depending on the differentiation status of HCC cells [31]. In general, well-differentiated HCC usually expresses relatively high levels of hepatocyte-specific genes, including ASGP-R; whereas poorly-differentiated HCC expresses minimal or no hepatocyte-specific genes, including ASGP-R [32]. In most cases, there exists the dramatic heterogeneity of liver-specific gene expression in human HCC tissues [33], and decreased expression of ASGP-R was observed in liver cancer tissue [34]. Therefore, using AF or other galactosylated or lactosylated residues to label LNPs for drug or gene delivery may not always be effective for patients with HCC, because HCC develops on a variety of disease backgrounds and there is a striking variation in ASGP-R expression levels in HCC from different patients. Using well-differentiated hepatoma cells, such as HepG2, Hep3B and Huh-7 cells, as an in vitro screening tool may not necessarily reflect targeting efficacy to tumor-specific distribution in vivo [35].

High density lipoprotein (HDL) has a high drug carry capacity, and can be recognized by HDL receptors on hepatocytes. Recombinant HDL was utilized to deliver an anti-HBV peptide (nosiheptide) to the liver, and it was shown to achieve a selective distribution in hepatoma cells in vitro and a preferential liver distribution in rats [36]. Apolipoprotein E is cleared by hepatocytes, and it has been employed to be carriers for small interfering RNA (siRNA) delivery to hepatocytes [37].

Given the fact that hepatic stellate cells (HSCs) are the major cell type responsible for hepatic fibrosis, a repairing process that causes excess production of extracellular matrix components and deposition of fibrotic scaring in chronically injured liver [38], much attention has been focused on targeting this cell type in the last decade. A couple of cell surface molecules that are overexpressed on activated HSCs during hepatic fibrogenesis, such as insulin growth factor receptor II [39], collagen type VI and platelet-derived growth factor (PDGF) receptor β-subunit [40] are selected as the cell surface targets. Drug carriers labeled with specific peptides recognizing these cell surface molecules, such as cyclic peptide containing arginine-glycine-aspartate (RGD)-labeled sterical lipid nanoparticles [3] or Mannose-6-phosphate human serum albumin (M6P/HAS) [41] exhibited HSC-selective distribution. The RGD cyclic peptide was recently used as a targeting molecule for the recognition of activated HSCs in two animal models for early diagnosis of hepatic fibrosis with a SPECT imaging modality [42]. Using the retinol binding protein (RBP) in activated HSCs seems to be very effective in delivering siRNA against gp46 (rat homolog of human heat shock protein 47), and inhibiting fibrosis in two animal models [43].

Targeting approaches for drug or gene delivery to other non-parenchymal cell types, such as Kupffer cells or sinusoidal endothelial cells, are summarized recently [27]. These approaches are crucial in delivering agents which are anti-inflammatory or anti-oxidants to these cell types due to the fact that Kupffer cells are pivotal in the mediation of inflammatory responses and subsequent fibrogenesis [44].

4. Polylipid nanoparticle-mediated liver gene delivery

Compared to drug delivery, LNP-mediated in vivo gene delivery is still in its development stage; and many issues that affect delivery approaches and efficacy remain to be solved. The main issues include: 1) the formation of aggregates between cationic lipids and serum proteins bearing negative charges; 2) the administration routes of LNP-DNA complexes (lipoplexes); 3) intracellular trafficking from the cytoplasm to the nucleus; 4) the proliferative state of cells to be transfected; and 5) transient transgene expression for a short duration [6, 45]. Substantial efforts have been made to address these issues in our previous studies and by others [8, 46, 47]. Particularly, we polymerized an acrylamide lipid to generate a polycationic lipid (PCL), which was able to interact with plasmid DNA effectively and form compacted complexes as demonstrated by Raman microspectral analysis [8]. PCL has a unique molecular configuration and molecular weight distribution as indicated by mass spectrophotometrical analysis [8]. Moreover, this lipid can be synthesized in a multiple gram quantity in a laboratory, and the synthetic approach is amendable for industrial production at a quantity sufficient enough for large animal use [8]. PLNP was formulated with a neutral lipid, cholesterol. The PLNP size was reduced to approximately 100 nm in diameter [7], and the Zeta potential of PLNP was decreased to neutral by neutralizing extra-positive charges with excess plasmid DNA [8]. Not only was this formulation of PLNP non-toxic, but it also displayed transfection efficiency equivalent to other commercially available transfection agents, such as Lipofectamine in hepatoma cell lines [7]. Moreover, high-resolution fluorescent deconvolution microscopy documented that PLNP-mediated gene transfection led to earlier GFP expression in hepatoma cells than Lipofectamine [8]. The unique feature of this formulation is that it is extremely serum-resistant, and exposure to cell culture medium containing 50% fetal bovine serum for 24 hours did not affect its size significantly. PLNP reacted up to 30-fold less with serum proteins or blood cells after intravenous administration in comparison with DOTAP-DOPE or DOTAP-Chol formulations [6]. This feature makes PLNP formulation particularly useful for in vivo gene transfer. In the subsequent studies, we have proved that it is very effective in the transfer of reporter genes or function genes to normal mouse livers as demonstrated in Fig. 2 by bioluminescent imaging of firefly luciferase gene expression 24 hours after portal vein injection of PLNP-plasmid DNA complexes (polyplexes) or preclinical models [48, 49].

Figure 2.

PLNP-mediated gene transfer into mice through portal vein injection. One day after the intravenous injection of polyplexes with pNDLux.2 plasmid encoding the firefly luciferase gene, the animal was imaged by CCD camera. The expression of luciferase was clearly shown in the liver area, demonstrating the effectiveness of this delivery approach and the applicability of a non-invasive imaging modality in the determination of transgene expression in animals.

We also developed an approach to promote normal hepatocytes to proliferate in situ without partial hepatectomy, which favors the transgene expression by lipofection but is not acceptable for clinical application [6]. Furthermore, placing an indwelling catheter in the portal vein allows repeated administration of polyplexes for sustained transgene expression [6]. All these efforts render our formulation of PLNP distinct from other lipid-based nanoparticles. Our animal experiments have clearly demonstrated that PLNP is characterized as extremely stable in the bloodstream, and highly effective in liver-based gene transfer when polyplexes are administrated through the portal vein [6, 17]. In comparison with other commonly used lipid formulations of nanoparticles, our formulation possesses the notable advantages essential for in vivo gene delivery as illustrated in Table 1.

CharacteristicsPCLPLNPLipofectamineDOTAP-Chol
Cationic lipidYesLNPLNPLNP
Particle size
(nm)
Irrelevant125±54358 ±85110±20
Size changes(50%FBS)Irrelevant100±20nm2206 ± 311 nm1050±100 nm
In vitro transfection efficiency Luciferase activity (in RLU)Irrelevant>10E7>10E7>10E7
Cytotoxicity (LDH release)Low or noneNormal10±3%
(>5%)
11±3.5%
(>5%)
Binding rate to serum proteinLowLowObvious20-30-fold higher than PLNP
In vivo stabilityIrrelevantStableNot determinedInstability
UsageRaw material for PLNPIn vitro or in vivo transfectionIn vitro transfectionIn vivo transfection

Table 1.

Comparison of common transfection agents for in vitro and in vivo application

The content in this table was summarized according to our previous publications [6-8]. FBS = fetal bovine serum. RLU = relative light unit. LDH = lactate dehydrogenase.


5. Preclinical trials for proof of the concept

In order to demonstrate that our PLNP formulation is effective in delivering functional genes to the liver, we established a liver injury model in mice caused by the treatment with D-galactosamine (D-Gal) and lipopolysaccharide (LPS). This combination of D-Gal/LPS treatment resulted in a profound acute liver injury characterized by massive liver cell death through apoptosis, elevation of serum alanine aminotransferase (ALT), significant oxidant stress, depletion of the reduced form of glutathione and enhanced lipid peroxidation [50]. In separate studies we have demonstrated that anti-oxidant enzyme such as extracellular superoxide dismutase (EC-SOD), SOD mimetics (MnTBAP) and catalase are effective in the prevention of hepatic toxicity caused by xenobiotics in primary hepatocytes or hepatoma cells [51-53], and they improved recipient survival and graft function and growth after small-for-size liver transplantation in rats [54]. Therefore, we chose the human EC-SOD gene as a functional gene to prove the feasibility. The EC-SOD gene product was exclusively secreted into the extracellular space and functions as an ROS scavenger. ROS are generated in both intracellular and extracellular spaces, and superoxide anions and hydrogen peroxide (H2O2) are able to cross the plasmatic membrane to enter the extracellular space [17]. It was found that two days after portal vein injection of EC-SOD polyplexes, liver EC-SOD gene expression was increased approximately 50-fold compared to the group receiving injection of control plasmid polyplexes, and serum SOD activity was increased accordingly. On the other hand, serum ALT was reduced to nearly one third in mice receiving EC-SOD polyplex injection compared to those with D-Gal/LPS challenge, along with improved liver histology, restored glutathione levels and decreased lipid peroxidation [48]. The findings of this preclinical trial confirmed the effectiveness of PLNP-mediated EC-SOD gene delivery to the liver, and that the delivery protected the mice from oxidant stress-associated liver injury. The results also indicate that this anti-oxidant gene delivery approach could be useful in attenuating xenobiotics or drug metabolite-induced toxicity to the liver.

Ischemia/reperfusion (I/R)-associated donor organ damage is inevitable in all solid organ transplantation, and is caused by enhanced oxidant stress with release of inflammatory cytokines, such as tumor growth factor-α (TNF-α) and interleukin 2 (IL-2). Although the precise molecular mechanism of the I/R-associated liver injury remains to be investigated, enhanced oxidant stress with release of superoxide anions or H2O2, depletion of the reduced form of glutathione and increased lipid peroxidation has been the key element in the pathogenesis in orthotopic liver transplantation (OLT) or small size liver graft transplantation (SSLGT) [54-56]. Thus, it is rational to use of antioxidant gene transfer to minimize oxidant stress and improve the donor organ quality and function after the implantation. We delivered either EC-SOD, catalase gene or in combination, using the same approach as described above. Two days after the delivery, the transgene expression was increased for 10-50-fold, with increased SOD or catalase activity in the mouse liver. This delivery led to a marked decrease in superoxide anion levels and H2O2 release along with a decrease in serum ALT levels, liver lipid peroxidation and dramatic improvement of liver histology [49]. This study was positively commented by two well-known hepatologists from Europe as an editorial, quoting “beyond a proof of the principle, the study could be the basis for studies with larger animals and may help bridge the gap between the basic understanding of pathophysiologic processes in animal models towards a practical clinical application in liver transplantation” [57]. The findings are especially applicable in living donor liver transplantation, for which small or margin donor livers were used for transplantation. Much more pronounced oxidant stress, a higher rate of graft failure, and retarded graft growth are found in small size liver transplantation than OLT [54, 58]. The margin grafts with small size or steatosis and fibrotic deposition are often used for transplantation in clinics due to severe shortage of donor organs.

6. Challenges in scaling-up and moving towards clinical applications

Our preclinical studies were performed in mice, and there are certainly a number of issues to face when this anti-oxidant gene therapy approach is considered to be evaluated in middle or large size animals such as rabbits, dogs, monkeys or pigs. The first issue is to scale-up, which includes the plasmid DNA generation, synthesis of PCL in a quantity, and formulation of PLNP at a volume sufficient enough for the use in large animals. More challenges exist regarding how to stimulate liver cells to proliferate in large animals and deliver polyplexes locally to the liver. Using a catheter through the femoral vein or jugular vein for retrograde administration into hepatic vein or passing into the portal vein for administration similar to the transjugular intrahepatic portosystemic shunt (TIPS) procedure, which is used to lower portal hypertension in cirrhotic patients, should be feasible in large animals when angiography and the administration are performed by an experienced specialist with the availability of angiographic devices. The latter method was used to administer adenoviral vector in baboons [59]. One trial of plasmid DNA injection into the hepatic vein by blocking the hepatic vein out-flow with an inflated balloon achieved high gene expression levels in selected pig liver lobes [30]. Safety concerns include amount of polyplexes to be administrated locally and the effects of the plasmid DNA, PLNP and polyplexes on the liver as well as systematically. LNP-mediated gene transfer is usually transient; therefore, there will be less concern for long-term effects of the transgene products on the host. However, immune reaction to human gene products in animals may occur if the transgene products are produced at sustained levels for a long period of time. It is preventable by administration of immunosuppressive agents, such as FK506. Moreover, innate immunity to plasmid DNA with bacterial unmethylated CG dinucleotide (CpG) can be eliminated by using CpG-free plasmid [60].

An additional concern is to establish a liver injury model to evaluate the effect of anti-oxidant gene transfer by PLNP in large animals. For pigs, exposure to a loading dose of 0.25 g/kg, maintaining the blood concentration of acetaminophen at 350-450 mg/dl, and adapting enteric maintenance dose of 1,000-3,000 mg/hour resulted in the onset of acute liver failure (prothrombin time value <30%) within 32±4.4 hours, and further mortality in 15.8±2.4 hours [61]. A large dose of acetaminophen intake causes significant oxidant stress and acute liver injury due to its metabolism and generation of an interactive metabolite, n-acetyl-p-benzoquinone imine (NAPQI), which binds to the cytoplasmic membrane, leads to lipid peroxidation, depletion of antioxidants, such as glutathione, and results in hepatic injury. Not only will the delivery of antioxidant genes with PLNP in a pig model of liver injury assess the therapeutic efficacy, but also take advantage of a regenerative response to the injury for high transgene expression. Alternatively, small size graft liver transplantation (SSGLT) at ≤50% graft volume could be performed in rabbits or pigs to mimic living donor liver transplantation in humans. Significant oxidant stress-associated injury and regenerative response in the small size grafts will be the best fit for the high transgene expression and ROS scavenging property of the gene product. Therefore, SSGLT may be considered to be a valuable model for evaluating the feasibility and efficacy of anti-oxidant gene transfer for small-for-size-associated graft failure in a transplant setting.

In summary, moving promising PLNP-mediated antioxidant gene transfer from small animals to large animals may face more challenges than discussed above, and it is even more challenging when further considering for clinical use, in terms of safety concern and administrative approval. Fig. 3 provides a schematic illustration of the roadmap from bench to bedsides of a potential biological therapy. The reality is that with limited funding opportunities from governmental or private agencies, to cope with multi-facet challenges at a large scale, it is less likely to reach the final goal in a short term. Attracting financial investments and taking advantages of cutting-edging technologies and vast resources from biopharmaceutical companies may advance this process in a fast pace. In this context, the net benefits would be the early clinical application of this promising antioxidant gene transfer in patients with critical needs and the financial return from the investment. We would foresee such a movement occurring in the near future.

Figure 3.

Translation roadmap of a potential gene therapy platform from bench to bedside. This illustration summarizes the major steps in moving a potential gene transfer approach from laboratory research to clinical trials. The actual actions could be more complicated than described. However, for the guarantee of patient safety, each new therapeutic agent must be well characterized, and evaluated in preclinical settings, and then move to large animals for feasibility assessment. The balance between therapeutic benefits and potential risks of an innovative therapy platform always leans on the patient safety as the first priority.

7. Conclusion and prospectives

Non-viral vector-mediated gene transfer has less concern in terms of integration-associated long-term transgene expression and insertion-induced mutation. In general, non-viral vector elicits minimal immune responses in contrast to adenoviral vectors [17]. However, non-viral vectors, such as lipid nanoparticles (LNPs) possess their own drawbacks when they are considered for in vivo use. One prominent issue is the interaction of cationic LNPs with serum protein and blood cells, and this causes a series of issues, such as instability of the lipoplexes or polyplexes and adverse effects to the host, including non-preferential distribution, embolism of the aggregates of lipoplex-protein or blood cells, and inflammatory responses. For these reasons, many gene transfer agents are very effective in cell culture; whereas they have less applicability in vivo. Up to date, only a few formulations of cationic LNPs have proved to be effective and safe in animals and have reached the stage of clinical trials, such as DOTAP-Chol and DC-Chol. Our PLNP formulation has a superior stability profile, and displayed much less reactivity to serum proteins and blood cells when compared to other commercially available formulations. At the same time, it has proved to be the most effective liver-based gene transfer agent [6]. Two preclinical trials with different models of oxidant-stress-associated liver injury have demonstrated the effectiveness of the anti-oxidant gene delivery in the liver, and the efficacy of the gene delivery in minimizing oxidant-stress, attenuating liver cell death, and improving liver histology [48, 49]. Further efforts have been made to move this promising PLNP-mediated anti-oxidant gene transfer technology from bench to bedside. The strategies in pushing this movement towards clinical trials include: 1) Scaling-up of the polycationic lipid production and generation of PLNPs; 2) Generation of specific antioxidant gene plasmids in a GMP facility at the standard for clinical use; 3) Establishing large animal models for safety and efficacy assessment; and 4) Preparation for obtaining administrative approval of clinical application. Although the clinical translation of this potential technology will need tremendous efforts, we anticipate that this technology will eventually reach to patients with critical needs as a novel therapy. Potential indications which may benefit from this therapy range from alcohol or drug toxicity to living donor liver transplantation with a margin graft. This technology is also applicable in oxidant stress-associated disorders in other systems, such as ischemic cardiac, pulmonary, brain or renal damage, etc. [17]. With the combination of our extensive expertise in drug and gene delivery, advanced knowledge and skills in liver injury, fibrosis, transplant and cancer research and practice, in addition to the engine of financial investment from various sources, such as venture capital and governmental support in entrepreneurship, we are optimistic to foresee the benefits of this technology in indicated patients in a near future. Nevertheless, the road to reach this goal will not be smooth, and various challenges demand powerful solutions.

Acknowledgments

The studies presented in the chapter were supported by the UC Davis Health System Award, American Liver Foundation Liver Scholar Award, UC Davis Technology Transfer Award, and the National Institute of Diabetes, Digestive and Kidney Diseases (DK069939) to JW. The commercialization and translation to clinical application of this technology is supported by the Nanjing Municipal Innovative Technology Award (321 Plan). Yahan Fan is the recipient of China Scholarship Council Award (201207610003).

Abbreviations used in the chapter

ASGP-R = asialoglycoprotein receptor; DOTAP = (dioleoyloxy)-3-(trimethylamonio) propane; DOPE = L-a dioleoyl phosphatidylethanolamine; EC-SOD = extracellular superoxide dismutase; HCC = hepatocellular carcinoma; LDLT = Living donor liver transplantation; LNP = lipid nanoparticles; OLT = orthotopic liver transplantation; PEG = polyethylene glycol; PLNP = polylipid nanoparticles; polyplex = PLNP-plasmid DNA complex; RES = reticuloendothelial system.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Yahan Fan and Jian Wu (February 27th 2013). Polylipid Nanoparticle, a Novel Lipid-Based Vector for Liver Gene Transfer, Gene Therapy - Tools and Potential Applications, Francisco Martin Molina, IntechOpen, DOI: 10.5772/54270. Available from:

chapter statistics

1739total chapter downloads

1Crossref citations

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

DNA Electrotransfer: An Effective Tool for Gene Therapy

By Aurore Burgain-Chain and Daniel Scherman

Related Book

First chapter

Photo- and Free Radical-Mediated Oxidation of Lipid Components During the Senescence of Phototrophic Organisms

By Jean-François Rontani

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us